홈 > 시장보고서 > 의약품 > 유전자 치료/RNAi

시장보고서

상품코드

1347189

미국 및 유럽의 유전자 편집 시장 예측(-2030년) - 기술, 제품 및 서비스, 용도, 최종 사용자별, 국가별 분석

US and Europe Gene Editing Market Forecast to 2030 - Country Analysis by Technology, Product and Service, Application, and End User

발행일: 2023년 08월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 146 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

미국 및 EU의 유전자 편집 시장은 2022년 39억 5,509만 달러에서 2030년 150억 5,292만 달러에 달할 것으로 예상되며, 2022-2030년간 연평균 18.2%의 성장률을 보일 것으로 예상됩니다.

암 및 기타 유전성 질환의 유병률 증가, 유전자 편집 도구의 지속적인 기술 발전과 같은 요인이 미국 및 EU 유전자 편집 시장의 성장을 가속할 것으로 예상됩니다. 또한, 생명 공학 분야의 기술 혁신과 투자 증가는 예측 기간 동안 미국 및 EU 유전자 편집 시장의 성장을 가속할 것으로 예상됩니다. 그러나 유전자 편집 방법의 높은 생산 비용은 미국 및 EU 유전자 편집 시장의 성장을 저해할 수 있습니다.

신제품 개발을 위한 시장 기업들의 전략적 노력으로 향후 미국 및 EU 유전자 편집 시장 확대 전망

헬스케어 IT의 기술 개발로 인해 인공지능(AI)이 CRISPR 시스템 제조에 사용될 수 있게 되었습니다. 헬스케어 IT 분야에서 일하는 개발자들은 제품 개발의 모든 단계를 제어하고 모니터링하기 위한 프로세스 분석에 종사하고 있습니다. 바이오마커 발굴부터 임상시험, 환자 모니터링에 이르는 기술 개발에 집중하고 있으며, AI를 디지털 제조에 활용하기 위한 전문 기술 도입에 착수한 기업들도 있습니다.2023년 2월, CRISPR, 합성생물학, 인공지능(AI) 기술을 개발하는 영국 옥스퍼드에 본사를 둔 신속 분자 검사 플랫폼을 개발하는 센스 바이오디텍션(Sense Biodetection)을 인수했습니다. 이번 인수를 통해 셜록은 최첨단 CRISPR 기반 진단법을 세계 소비자의 손에 편리하게 전달할 수 있는 능력을 가속화할 수 있게 됐습니다.

2020년 1월, ERS Genomics와 New England Biolab은 CRISPR 유전자 변형 도구 및 시약의 개발 및 상용화를 위해 협력했으며, New England Biolab은 유전체 연구를 위한 가장 다양한 재조합 효소 및 네이티브 효소 제품군을 제공합니다. 이 회사는 유전자 편집을 포함한 새로운 연구 분야에 대한 제품 제공을 지속적으로 확대하고 있으며, CRISPR/Cas9 시약 및 도구 제공 업체로서 NEB는 ERS Genomics의 라이선스를 통해 이러한 기술을 사용 및 판매할 수 있는 권리를 확대했습니다.

따라서 이러한 노력은 유전자 편집을 촉진하고 향후 몇 년동안 미국 및 EU의 유전자 편집 시장의 성장을 가속할 것으로 예상됩니다.

미국 및 EU 유전자 편집 시장은 기술, 제품 및 서비스, 응용 분야, 최종 사용자에 따라 분류됩니다. 기술 기반으로는 CRISPR, TALEN, 안티센스, 징크 핑거 뉴클레아제(ZFNs) 및 기타로 분류되며, 2022년에는 CRISPR 부문이 미국 및 EU 유전자 편집 시장에서 가장 큰 점유율을 차지했습니다. 또한, 같은 부문은 향후 몇 년동안 가장 빠른 속도로 성장할 것으로 예상됩니다. 제품 및 서비스를 기준으로 시약 및 소모품, 장비 및 기타로 분류되며, 2022년에는 시약 및 소모품 부문이 미국 및 EU 유전자 편집 시장에서 가장 큰 점유율을 차지했습니다. 또한 이 부문은 향후 몇 년동안 가장 빠른 속도로 성장할 것으로 예상됩니다. 용도별로는 세포주 공학, 유전공학, 진단용, 신약개발, 기타로 구분되며, 2022년에는 세포주 공학 분야가 가장 큰 시장 점유율을 차지했습니다. 또한, 이 부문은 향후 몇 년동안 가장 빠른 속도로 성장할 것으로 예상됩니다. 최종 사용자에 따라 제약 및 생명공학 기업, 학술 및 연구 기관, 계약 연구 기관(CRO), 기타로 분류되며, 2022년에는 제약 및 생명공학 기업 부문이 미국 및 EU 유전자 편집 시장에서 가장 큰 점유율을 차지했습니다. 그러나 학술 및 연구 기관 부문은 향후 몇 년동안 가장 빠른 속도로 성장할 것으로 예상됩니다.

세계보건기구(WHO), 농업유전체연구센터(CRAG), 질병통제예방센터(CDC), 환경식품농촌지역부(DEFRA), 식량농업기구(FAO), 미국 식품의약국(FDA), 이탈리아 농업유전체학회(SIGA) 등이 미국 및 EU의 유전자교정 시장에 관한 보고서를 작성할 때 참고한 1차 및 2차 조사 정보의 일부입니다.

The factors such as rise in the prevalence of cancer and other genetic disorders and continuous technological advancements in gene editing tools are expected to drive the US & EU gene editing market growth. Moreover, growing innovations and rising investments in biotechnology is also expected to foster the US & EU gene editing market growth during the forecast period. However, the high cost of production of gene editing methods may hinder the US & EU gene editing market growth.

Strategic Initiatives by Market Players to Develop New Products to Boost the US & EU Gene Editing Market in Future

Technological developments in healthcare IT allow the use of artificial intelligence (AI) for manufacturing CRISPR Systems. Developers working in the healthcare IT domain are engaged in analyzing the processes to control and monitor all the stages of product development. The focus is to develop technologies from discovering biomarkers to clinical trials and patient monitoring. A few companies have initiated implementing their expertise to use AI for digital manufacturing. In February 2023, Sherlock Biosciences, which develops CRISPR, synthetic biology, and artificial intelligence (AI) technologies, acquired Sense Biodetection, an Oxford, UK-based developer of a rapid molecular testing platform. This acquisition accelerates Sherlock's ability to put the most advanced CRISPR-based diagnostics conveniently in the hands of global consumers.

In January 2020, ERS Genomics and New England Biolab collaborated to develop and commercialize CRISPR gene modification tools and reagents. New England Biolab offers the largest selection of recombinant and native enzymes for genomic research. The company continues expanding its product offerings into new research areas, including genome editing. As a provider of CRISPR/Cas9 reagents and tools, NEB's license from ERS Genomics expands the company's rights to use and sell these technologies.

Thus, such initiatives are expected to foster genome editing and enhance the US & EU gene editing market growth in the coming years.

The US & EU gene editing market is segmented on the basis of technology, product and services, application, and end user. Based on the technology is segmented into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. In 2022, the CRISPR segment held the largest share of the US & EU gene editing market. Moreover, the same segment is also expected to grow at the fastest rate during the coming years. Based on the products and services is segmented into reagents and consumables, instruments, and others. In 2022, the reagents and consumables segment held the largest share of the US & EU gene editing market. Moreover, the same segment is also expected to grow at the fastest rate during the coming years. Based on the application is segmented into cell line engineering, genetic engineering, diagnostic application, drug discovery, and others. In 2022, the cell line engineering segment held the largest share of the market. Moreover, the same segment is also expected to grow at the fastest rate during the coming years. Based on the end user is segmented into pharmaceutical & biotechnology companies, academic and research institutes, contract research organization (CROs), others. In 2022, the pharmaceutical & biotechnology companies segment held the largest share of the US & EU gene editing market. However, the academic and research institutes segment is expected to grow at the fastest rate during the coming years.

The World Health Organization (WHO), Centre For Research in Agricultural Genomics (CRAG), Centers for Disease Control and Prevention (CDC), Department For Environment, Food, And Rural Affairs (DEFRA), Food And Agricultural Organization (FAO), US Food and Drug Administration (FDA), Italian Society of Agricultural Genetics (SIGA) are among some of the primary and secondary sources referred to while preparing the report on the US & EU gene editing market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the US and Europe Gene editing market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the US and Europe Gene editing market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 US and Europe Gene Editing Market- By Technology
- 1.3.2 US and Europe Gene Editing Market- By Products and Services
- 1.3.3 US and Europe Gene Editing Market- By Application
- 1.3.4 US and Europe Gene Editing Market- By End User
- 1.3.5 Gene Editing Market- By Geography

2. Executive Summary

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. US and Europe Gene Editing Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 US - PEST Analysis
- 4.2.2 Europe - PEST Analysis
4.3 Expert Opinions

5. Gene Editing Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rise in Prevalence of Cancer and Other Genetic Disorders
- 5.1.2 Continuous Technological Advancements in Gene Editing Tools
5.2 Market Restraints
- 5.2.1 High Cost of Production of Gene Editing Methods
5.3 Market Opportunities
- 5.3.1 Growing Biotechnology Industry in US and Europe
5.4 Future Trends
- 5.4.1 Strategic Initiatives by Market Players to Develop New Products
5.5 Impact Analysis

6. Gene Editing Market - US and Europe Analysis

6.1 US and Europe Gene Editing Market Revenue Forecast and Analysis
6.2 Market Positioning of Key Players

7. US and Europe Gene Editing Market Analysis - By Technology

7.1 Overview
- 7.1.1 US and Europe Gene Editing Market, By Technology 2022 & 2030 (%)
7.2 CRISPR
- 7.2.1 Overview
- 7.2.2 US and Europe CRISPR Market Revenue and Forecasts to 2030 (US$ Million)
7.3 TALEN
- 7.3.1 Overview
- 7.3.2 US and Europe TALEN Market Revenue and Forecasts to 2030 (US$ Million)
7.4 Antisense
- 7.4.1 Overview
- 7.4.2 US and Europe Antisense Market Revenue and Forecasts to 2030 (US$ Million)
7.5 Zinc Finger Nucleases (ZFNs)
- 7.5.1 Overview
- 7.5.2 US and Europe Zinc Finger Nucleases (ZFNs)Market Revenue and Forecasts to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)

8. US and Europe Gene Editing Market Analysis - By Products and Services

8.1 Overview
- 8.1.1 US and Europe Gene Editing Market, By Products and Services 2022 & 2030 (%)
8.2 Reagents and Consumables
- 8.2.1 Overview
- 8.2.2 US and Europe Reagents and Consumables Market Revenue and Forecasts to 2030 (US$ Million)
8.3 Instruments
- 8.3.1 Overview
- 8.3.2 US and Europe Instruments Market Revenue and Forecasts to 2030 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)

9. US and Europe Gene Editing Market Analysis - By Application

9.1 Overview
- 9.1.1 US and Europe Gene Editing Market, By Application 2022 & 2030 (%)
9.2 Cell Line Engineering
- 9.2.1 Overview
- 9.2.2 US and Europe Cell Line Engineering Market Revenue and Forecasts to 2030 (US$ Million)
9.3 Genetic Engineering
- 9.3.1 Overview
- 9.3.2 US and Europe Genetic Engineering Market Revenue and Forecasts to 2030 (US$ Million)
9.4 Diagnostic Application
- 9.4.1 Overview
- 9.4.2 US and Europe Diagnostic Application Market Revenue and Forecasts to 2030 (US$ Million)
9.5 Drug Discovery
- 9.5.1 Overview
- 9.5.2 US and Europe Drug Discovery Market Revenue and Forecasts to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)

10. US and Europe Gene Editing Market Analysis - By End User

10.1 Overview
- 10.1.1 US and Europe Gene Editing Market, By End User 2022 & 2030 (%)
10.2 Pharmaceutical & Biotechnology Companies
- 10.2.1 Overview
- 10.2.2 US and Europe Pharmaceutical & Biotechnology Companies Market Revenue and Forecasts to 2030 (US$ Million)
10.3 Academic and Research Institutes
- 10.3.1 Overview
- 10.3.2 US and Europe Academic and Research Institutes Market Revenue and Forecasts to 2030 (US$ Million)
10.4 Contract Research Organization (CROs)
- 10.4.1 Overview
- 10.4.2 US and Europe Contract Research Organization (CROs) Market Revenue and Forecasts to 2030 (US$ Million)
10.5 Others
- 10.5.1 Overview
- 10.5.2 US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)

11. US and Europe Gene Editing Market Analysis

11.1 US Gene Editing Market Revenue Forecast and Analysis
- 11.1.1 Overview
- 11.1.2 US: Gene Editing Market - Revenue and Forecasts to 2030 (USD Million)
- 11.1.3 US: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
- 11.1.4 US: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
- 11.1.5 US: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
- 11.1.6 US: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
11.2 Europe Gene Editing Market Revenue Forecast and Analysis
- 11.2.1 Overview
- 11.2.2 Europe: Gene Editing Market - Revenue and Forecasts to 2030 (USD Million)
- 11.2.3 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
- 11.2.4 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
- 11.2.5 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
- 11.2.6 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
- 11.2.7 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Country (%)
- 11.2.8 Germany: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.8.1 Germany: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.8.2 Germany: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
  - 11.2.8.3 Germany: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
  - 11.2.8.4 Germany: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
  - 11.2.8.5 Germany: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
- 11.2.9 UK: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.9.1 UK: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.9.2 UK: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
  - 11.2.9.3 UK: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
  - 11.2.9.4 UK: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
  - 11.2.9.5 UK: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
- 11.2.10 France: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.10.1 France: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.10.2 France: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
  - 11.2.10.3 France: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
  - 11.2.10.4 France: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
  - 11.2.10.5 France: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
- 11.2.11 Italy: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.11.1 Italy: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.11.2 Italy: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
  - 11.2.11.3 Italy: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
  - 11.2.11.4 Italy: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
  - 11.2.11.5 Italy: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
- 11.2.12 Spain: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.12.1 Spain: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.12.2 Spain: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
  - 11.2.12.3 Spain: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
  - 11.2.12.4 Spain: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
  - 11.2.12.5 Spain: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
- 11.2.13 Rest of Europe: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.13.1 Rest of Europe: Gene Editing Market - Revenue and Forecast to 2030 (USD Million)
  - 11.2.13.2 Rest of Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
  - 11.2.13.3 Rest of Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
  - 11.2.13.4 Rest of Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
  - 11.2.13.5 Rest of Europe: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in US and Europe Gene Editing Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Thermo Fisher Scientific Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Merck KGaA
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Lonza Group AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Horizon Discovery Group plc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Integrated DNA Technologies, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 GenScript Biotech Corporation
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 New England Biolabs
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Eurofins Scientific SE
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 CRISPR Therapeutics
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Editas Medicine Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 ElevateBio LLC
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments

14. Appendix

14.1 Glossary of Terms

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 3,450

￦ 4,895,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 4,450

￦ 6,314,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,450

￦ 7,734,000

※ 부가세 별도

미국 및 유럽의 유전자 편집 시장 예측(-2030년) - 기술, 제품 및 서비스, 용도, 최종 사용자별, 국가별 분석

US and Europe Gene Editing Market Forecast to 2030 - Country Analysis by Technology, Product and Service, Application, and End User

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 미국 및 유럽의 유전자 편집 시장 - 시장 구도

제5장 유전자 편집 시장 - 주요 시장 역학

제6장 유전자 편집 시장 : 미국과 유럽 분석

제7장 유전자 편집 시장 미국 및 유럽의 유전자 편집 시장 분석 - 기술별

제8장 미국 및 유럽의 유전자 편집 시장 분석 - 제품 및 서비스별

제9장 미국 및 유럽의 유전자 편집 시장 분석 - 용도별

제10장 유럽 및 미국 유전자 편집 시장 분석 : 최종사용자별

제11장 미국 및 유럽의 유전자 편집 시장 분석

제12장 업계 상황

제13장 기업 개요

제14장 부록